With its broad jurisdiction and resources, the FDA is uniquely positioned to lead the campaign against dangerous adulterations of GLP-1 medications in the U.S
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 1316 January 2025
Mol Metab 30:72130 Foer D, Beeler PE, Cui J, Karlson EW, Bates DW, Cahill KN (2021) Asthma exacerbations in patients with type 2 diabetes and asthma on Glucagon-like Peptide-1 receptor agonists
New data results from the pharmacokinetic study show that AGENT DCBs paclitaxel drug delivers superior retention to Selution SLR DEBs sirolimus drug
This results in a reduced appearance of fine lines and improved overall skin texture
Cholesterol and Lipid Profile Changes The lipid panel improvements with Retatrutide treatment represent some of the most clinically significant cardiovascular benefits